ehealth digital library

Digital library of
the Tanzania
health
community

Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African Infants.

Gargano, N., Madrid, L., Valentini, G., D'Alessandro, U., Halidou, T., Sirima, S., Tshefu, A., Mtoro, A., Gesase, S. and Bassat, Q. (2018) Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African Infants. Antimicrobial agents and chemotherapy, 62 (1). ISSN 1098-6596

[img]
Preview
PDF
Nicola Gargano.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (727kB) | Preview

Abstract

Artemisinin combination therapies are considered the mainstay of malaria treatment, but pediatric-friendly formulations for the treatment of infants are scarce. We sought to evaluate the efficacy and safety of a new dispersible-tablet formulation of dihydroartemisinin/piperaquine phosphate (DHA/PQP) in comparison to the marketed tablet (Eurartesim) in the treatment of infants with uncomplicated Plasmodium falciparum malaria. Reported here are the results of a large phase II, randomized, open-label, multicenter trial conducted in African infants (6 to 12 months of age) from Mozambique, Burkina Faso, The Gambia, the Democratic Republic of the Congo, and Tanzania. Primary efficacy endpoint was the PCR-corrected adequate clinical and parasitological response (ACPR) at day 28. Analysis was performed for the intention-to-treat (ITT) and per-protocol (PP) populations. A total of 201 patients received the dispersible-tablet formulation, and 99 received the conventional one administered as crushed tablets. At day 28, the PCR-corrected ACPRs were 86.9% (ITT) and 98.3% (PP) in the dispersible-tablet group and 84.9% (ITT) and 100% (PP) in the crushed-tablet group. At day 42, these values were 85.9% (ITT) and 96.5% (PP) in the dispersible-tablet group and 82.8% (ITT) and 96.4% (PP) in the crushed-tablet group. The comparison between survival curves for time to new infections showed no statistically significant differences (P = 0.409). The safety and tolerability profile for the two groups was similar in terms of type and frequency of adverse events and was consistent with that expected in African infants with malaria. A standard 3-day treatment with the new dispersible DHA/PQP formulation is as efficacious as the currently used tablet in African infants and has a comparable safety profile. (This trial was registered at ClinicalTrials.gov under registration no. NCT01992900.).

Item Type: Article
Keywords: Africa, Antimalarial agents, Dihydroartemisinin-piperaquine, Infants, Malaria
Subjects: Malaria > Diagnosis & treatment
Divisions: Ifakara Health Institute > Interventions
Depositing User: Mr Joseph Madata
Date Deposited: 13 Jan 2018 09:43
Last Modified: 13 Jan 2018 09:43
URI: http://ihi.eprints.org/id/eprint/4286

Actions (login required)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics